Yuval Eyal, Founder & CEO
What do you do in mydimed?
mydimed operates checkmymeds.org, a platform for medication consultation and medication therapy management. we help people who take multiple medication to avoid side effects and unnecessary hospital visits.
Can you share some recent development you've had?
With Telehealth market more than doubling in size during the COVID-19 pandemic, CheckMyMeds see a great opportunity to license it's platform to telehealth operators and digital health providers around medication management.
What was perceived as the future of healthcare in January 2020 is De Facto the technology in September 2020, as a result of Covid-19 pandemic.
What do you think is in for the company in the near – and far – future?
The company has a running platform that service clients (consumers) today. In order to execute our B2B product strategy, the company is dependent on raising capital. Management is working to raise funds and grants. The company was accepted to the MATTER digital health hub in Chicago, and as part of it, gaining access to U.S clients and partners.
What was perceived as the future of healthcare in January 2020 is De Facto the technology in September 2020, as a result of Covid-19 pandemic. The use of digital health tools and Telehealth became a standard, along with remote monitoring and medication delivery. The future of our field of medication therapy is Pharmaco-genetics, a field that relies on genetic data for medication treatment optimization. Medication therapy and medication consultation utilizing genetic data is the future of our field.
Did the COVID-19 pandemic affect you in any way? If so – how? And how did you handle it?
Covid-19 gave our market a boost, resulting in great impact to our company!
Learn more about mydimed!
-----
Samurai invested in mydimed as part of the activities of our 5th fund in Israel!
Want to join the family? Apply for a Samurai investment now